

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (review of TA613) [ID6307]

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Alimera Sciences (fluocinolone acetonide) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency for Equality • Cancer Black Care • Cancer Equality • Diabetes Research & Wellness Foundation • Diabetes UK • Eyecare Trust • Fight for Sight • Guide Dogs • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Juvenile Diabetes Research Foundation (JDRF) • Macmillan Cancer Support • Macular Society • Maggie's Centres • Marie Curie • National Federation of the Blind of the UK • Organisation of Blind African Caribbeans (OBAC) • Royal National Institute of Blind People (RNIB) • SeeAbility • Sense • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • Thomas Pocklington Trust 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Council for the Blind • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (dexamethasone intravitreal implant) • Bayer (aflibercept) • Biogen Biosimilars (ranibizumab) • Celltrion Healthcare • Genus Pharmaceuticals (bevacizumab and ranibizumab) • Novartis Pharmaceuticals (brolocizumab and ranibizumab) • Organon Pharma (bevacizumab) • Pfizer (bevacizumab)

Provisional stakeholder list for evaluation of fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (review of TA613) [ID6307]

Issue date: August 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Optometrists • British and Irish Orthoptic Society • British Geriatrics Society • British Oncology Pharmacy Association • British Ophthalmic Anaesthesia Society (BOAS) • British Psychosocial Oncology Society • Cancer Research UK • College of Optometrists • Optical Confederation • Royal College of General Practitioners • Royal College of Nursing • Royal College of Ophthalmologists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Roche (bevacizumab and faricimab) • Sanofi (aflibercept) • Teva UK (ranibizumab) • Thornton & Ross (bevacizumab) • Zentiva (bevacizumab) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Eyes and Vision Group • Cochrane UK • Eye Hope • Genomics England • Institute of Cancer Research • Institute of Ophthalmology, University College London • MRC Clinical Trials Unit • National Eye Research Centre • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.